Back to Search
Start Over
Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation
- Source :
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 28(2)
- Publication Year :
- 2021
-
Abstract
- Background Engraftment syndrome (ES) is a common complication of autologous hematopoietic cell transplantation (HCT). The difference in incidence of ES between melphalan formulations has not been widely reported throughout the literature and would allow for a more comprehensive understanding of the advantages and disadvantages of both melphalan formulations. Patients and methods This retrospective, single-center, observational study evaluated 83 adult multiple myeloma and immunoglobulin light chain amyloidosis patients who received either propylene glycol-containing (PG) or propylene glycol-free (PG-free) melphalan 140 mg/m2 as single-agent conditioning chemotherapy for autologous HCT from May 31, 2015 to May 31, 2019. The primary outcome was to assess the incidence of ES, as defined using the Maiolino criteria, with both melphalan formulations. Secondary outcomes included an analysis of potential risk factors for the development of ES, as well as an evaluation of overall length of stay (LOS). Results The incidence of ES for PG and PG-free melphalan did not differ significantly, 14/39 (35.9%) and 12/44 (27.3%) (P = 0.4), respectively. No potential risk factors for ES were identified on multivariate logistic regression analysis. A statistically significant difference in number of days to engraftment was identified for PG and PG-free melphalan, 15.56 vs. 13.82 days (P = 0.01), respectively; although, this did not translate to a decrease in LOS, 19.9 vs. 18.59 days (P = 0.14). Conclusions The incidence of ES did not differ significantly between melphalan formulations. Future research is needed to determine whether the faster time to engraftment seen with PG-free melphalan may translate to a decrease in LOS.
- Subjects :
- Melphalan
medicine.medical_specialty
Transplantation Conditioning
Engraftment Syndrome
Gastroenterology
Transplantation, Autologous
Immunoglobulin Light-chain Amyloidosis
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
Pharmacology (medical)
Multiple myeloma
Retrospective Studies
business.industry
Incidence (epidemiology)
Amyloidosis
Incidence
Hematopoietic Stem Cell Transplantation
medicine.disease
Transplantation
Oncology
030220 oncology & carcinogenesis
Complication
business
Multiple Myeloma
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 1477092X
- Volume :
- 28
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- Accession number :
- edsair.doi.dedup.....d0aa7ee8bfc8282d1468f7fb438fa075